NEW YORK (GenomeWeb News) – UK cancer biomarker firm Abcodia today announced a collaboration with the Austrian Institute of Technology to validate biomarkers for the early detection of lung and colorectal cancers.

Accessing a longitudinal collection of serum samples derived from a population cohort involved in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), Abcodia and AIT will design longitudinal studies to validate panels of biomarkers.

UKCTOCS is a randomized controlled trial for assessing the effect of screening on mortality.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.